Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Teames

Anesthesiology Fort Worth, TX Medical Doctor

NPI 1255686143 CMS profile 1365064

1500 South Main Street, Fort Worth, TX 76104

Open in the dashboard

General payments

$745,639

992 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Teames of Fort Worth, TX is reported in the CMS Open Payments database as having received $745,639 across 992 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $119,688 197
2024 General $100,472 135
2023 General $116,825 141
2022 General $147,680 208
2021 General $71,958 93
2020 General $91,882 98
2019 General $97,134 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Teames
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Richard Teames were reported at $119,688. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Richard Teames Anesthesiology median Middle half National median
2019 $97,134 $72 $23–$151 $163
2020 $91,882 $36 $17–$120 $114
2021 $71,958 $49 $21–$135 $132
2022 $147,680 $52 $22–$144 $149
2023 $116,825 $53 $23–$143 $160
2024 $100,472 $55 $25–$150 $164
2025 $119,688 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $669,458 920 payments
  2. Mindray DS USA, Inc. $34,620 23 payments
  3. Avanos Medical $27,979 30 payments
  4. FUJIFILM SonoSite, Inc. $13,182 7 payments
  5. Pajunk Medical Systems, LP $191 2 payments
  6. Merck Sharp & Dohme Corporation $73 5 payments
  7. Edwards Lifesciences Corporation $68 3 payments
  8. KARL STORZ Endoscopy-America $40 1 payment
  9. Eagle Pharmaceuticals, Inc. $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $332,946 89 payments
  2. Honoraria $160,905 51 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $144,520 39 payments
  4. Travel and Lodging $94,396 520 payments
  5. Food and Beverage $10,771 292 payments
  6. Education $2,100 1 payment
Products named General payments · program years 2019–2025
  1. Exparel Pain Management $496,399 710 payments
  2. EXPAREL Pain Management $147,215 174 payments
  3. Iovera $36,150 59 payments
  4. ON-Q $27,555 16 payments
  5. Zilretta Pain Management $21,007 30 payments
  6. A5 ANESTHESIA SYSTEM $18,918 11 payments
  7. iovera System $17,192 13 payments
  8. Zilretta Pain Management $12,705 21 payments
  9. TE X $9,740 6 payments
  10. SONOSITE PX ULTRASOUND SYSTEM $8,496 4 payments
  11. Other $11,918 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$30,165

Medicare's payments for the services billed

Medicare patients

260

Average age 73

Services billed

317

147 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 33%
Ischemic heart disease 30%
Chronic kidney disease 28%
Depression 26%
Cancer 20%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $84,357
$84,357 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $533
$533 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

992 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record